Gapping down
In reaction to disappointing earnings/guidance:
- FOSL -27.9%, EYPT -24.2%, BAND -17.8%, TPIC -15.2%, PBYI -15.1%, ROKU -14.7%, GLUU -13.5%, INSG -13.4%, EXPE -12.6%, AAOI -10.3%, HL -10.1%, VERI -10%, RUBI -9.4%, QTWO -9.3%, VIVO -7.9%, UPWK -7.8%, RP -7.3% (also announced acquisition of Buildium), LCI -6.9%, QUOT -6.7% (also announced retirement of CFO Ronald Fior and acquisition of Ubimo), RLGY -6.3%, FSCT -5.7%, CVNA -5.5%, KGC -5%, TRIP -4.9% (also announced strategic partnership with Trip.com Group [TCOM]), STAY -4.9%, PGTI -4.9%, COMM -4.7%, RCII -4.2%, PLUG -4.2%, EQH -3.7% (also authorized $400 mln share repurchase program), BIP -3.6%, HIMX -3.4%, EAF -3.3%, TELL -3%, SEAS -2.7%, NCLH -2.5%, NVTA -2.1%, BRKS -1.8%, INSW -1.8%, IAG -1.6%, GTN -1.6%, VSLR -1.5%, SUN -1.5%, TPC -1.3%, DCP -1.3%, LOPE -1%
Other news:
- QTNT -5.7% (prices offering of 12 mln shares of common stock at $7.00 per share)
- EOLS -3.2% (prices offering of 5,217,000 shares of common stock at $13.00 per share)
- YETI -3.2% (prices secondary offering of 10.0 mln shares at $29.00/share)
- AM -2.3% (prices offering of 25,965,437 shares of common stock by selling shareholders with gross proceeds expected to be $171 mln)
- DRRX -2.1% (to host key opinion leader conference call for DUR-928 Phase 2a alcoholic hepatitis study)
Analyst comments:
- IONS -1.4% (downgraded to Underweight from Equal-Weight at Morgan Stanley)
- TWTR -1.3% (downgraded to Underperform from In-line at Evercore ISI)
- DVA -1% (downgraded to Mkt Perform from Outperform at Raymond James)